<p>a) BMDCs from <i>wt</i> and <i>Tlr4</i><sup><i>-/-</i></sup> mice were stimulated with LPS (100ng/ml), LNFPIII-Dex (50μg/ml), Dex (50μg/ml) or nothing for 15 mins. Raf-1 kinase activity was carried out as described in materials and methods. The reaction mixtures were fractionated using SDS-PAGE and western blot performed with anti-phospho MBP antibody. b) RAW264.7 macrophages were pre-treated with anti-CD14 antibody and isotype control followed by stimulation with LPS (100ng/ml), LNFPIII-NGC (50μg/ml), Dex (50μg/ml) or nothing for 15 mins, processed for Raf-1 kinase assay and western blot analysis was performed using anti-phospho-MBP antibody.</p
<p>Wild-type and WASP15 Tg (#1) BMDMs were stimulated with (A) LPS or (B) TNF-α for the time indicat...
<p>(<b>A</b>) MDMs were treated with TLR2 agonist (Pam3CSK4, 1 µg/ml), TLR4 agonist (MPLA, 1 µg/ml) ...
<p>(A) BMM were stimulated with 1 µg/ml LPS and DMSO (control), proteasomal inhibitor (10 µM MG132),...
<p>a-b) RAW 264.7 cells were pretreated with Raf-1 inhibitors against Raf-1 (GW5074) or DMSO (a) for...
<p>a) HEKTLR4_AP (HEK293 cells stably transfected with TLR4/MD2/CD14 and alkaline phosphatase report...
<p>a-b) BMDCs from WT and CD14-/- mice were stimulated with LPS (100ng/ml), LNFPIII-NGC (50μg/ml), D...
The milk pentasaccharide LNFPIII has therapeutic action for metabolic and autoimmune diseases and pr...
<p>Peritoneal macrophages were isolated from both WT and conditional gp96-KO and treated with lipopo...
<p>a) HEKTLR4_AP cells were pretreated with anti-CD14 antibody or isotype control for 90 mins at 37˚...
<p>DCs derived from C57BL6 (B6 WT), TLR2<sup>−/−</sup>, C3H/HeOuJ (C3H WT), C3H/HeJ (TLR4 mutant) (A...
<p>(<b>A</b>) Primary bone marrow derived macrophages were treated with either DMSO, 1 µM 5z-7-Oxoze...
<p>(A) Response of Raw264.7 macrophages to LPS. Raw264.7 macrophages were plated and incubated overn...
<p>A) Peritoneal macrophages from WT, conditional gp96-KO and Tlr4-KO mice were treated with LPS for...
<p>Bone marrow-derived macrophages were prepared from A (<i>Ccs3<sup>S</sup></i>) and B6 (<i>Ccs3<su...
<p>(A) NIH-3T3 cells were transduced with retroviral vectors expressing M45 or GFP. Two days after t...
<p>Wild-type and WASP15 Tg (#1) BMDMs were stimulated with (A) LPS or (B) TNF-α for the time indicat...
<p>(<b>A</b>) MDMs were treated with TLR2 agonist (Pam3CSK4, 1 µg/ml), TLR4 agonist (MPLA, 1 µg/ml) ...
<p>(A) BMM were stimulated with 1 µg/ml LPS and DMSO (control), proteasomal inhibitor (10 µM MG132),...
<p>a-b) RAW 264.7 cells were pretreated with Raf-1 inhibitors against Raf-1 (GW5074) or DMSO (a) for...
<p>a) HEKTLR4_AP (HEK293 cells stably transfected with TLR4/MD2/CD14 and alkaline phosphatase report...
<p>a-b) BMDCs from WT and CD14-/- mice were stimulated with LPS (100ng/ml), LNFPIII-NGC (50μg/ml), D...
The milk pentasaccharide LNFPIII has therapeutic action for metabolic and autoimmune diseases and pr...
<p>Peritoneal macrophages were isolated from both WT and conditional gp96-KO and treated with lipopo...
<p>a) HEKTLR4_AP cells were pretreated with anti-CD14 antibody or isotype control for 90 mins at 37˚...
<p>DCs derived from C57BL6 (B6 WT), TLR2<sup>−/−</sup>, C3H/HeOuJ (C3H WT), C3H/HeJ (TLR4 mutant) (A...
<p>(<b>A</b>) Primary bone marrow derived macrophages were treated with either DMSO, 1 µM 5z-7-Oxoze...
<p>(A) Response of Raw264.7 macrophages to LPS. Raw264.7 macrophages were plated and incubated overn...
<p>A) Peritoneal macrophages from WT, conditional gp96-KO and Tlr4-KO mice were treated with LPS for...
<p>Bone marrow-derived macrophages were prepared from A (<i>Ccs3<sup>S</sup></i>) and B6 (<i>Ccs3<su...
<p>(A) NIH-3T3 cells were transduced with retroviral vectors expressing M45 or GFP. Two days after t...
<p>Wild-type and WASP15 Tg (#1) BMDMs were stimulated with (A) LPS or (B) TNF-α for the time indicat...
<p>(<b>A</b>) MDMs were treated with TLR2 agonist (Pam3CSK4, 1 µg/ml), TLR4 agonist (MPLA, 1 µg/ml) ...
<p>(A) BMM were stimulated with 1 µg/ml LPS and DMSO (control), proteasomal inhibitor (10 µM MG132),...